Drug Profile
DPS 102
Alternative Names: DPS-102Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Dermipsor
- Class Antipsoriatics; Nonsteroidal anti-inflammatories
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Psoriasis in Israel (Topical)
- 07 Oct 2008 Phase-I clinical trials in Psoriasis in Israel (Topical)